IBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD Horizon
HIBD Horizon

Part 4 · The future · 18/22

Future leads

The main molecules in Phase 1 and 2: further off in time, but full of hope.

How a medicine reaches us
Phase 1Is it safe? A few dozen people.
Phase 2Does it work? A few hundred.
Phase 3Confirming it on a large scale. Hundreds to thousands.
AuthorisedYour doctor can prescribe it.
Reading the bar:blue = stage passed, yellow = stage under way.

Against strictures (narrowings)

The first treatments that target scarring in the gut, not just inflammation.

Ontunisertib

Agomab · Tablet

Pathway: TGF-β / ALK5

Acts only in the gut. Strictures stable for up to 60 weeks in the 1st trial.

Crohn'sPhase 2b started in October 2026 (320 patients)
Possible arrival: after 2030

PALI-2108

Palisade Bio · Tablet

Pathway: PDE4

Switched on only in the gut.

Crohn'sPhase 1b in 6 patients: encouraging signals
UCPhase 2b under way
Possible arrival: after 2030

MBF-118

Medibiofarma (Spain) · Tablet

Pathway: PPARγ

Anti-scarring and anti-inflammatory.

Crohn'sPhase 2a completed, large Phase 2 in preparation
Possible arrival: after 2030

Duvakitug

Sanofi and Teva · Infusion then injection

Pathway: TL1A

The anti-TL1A drug will soon be tested on strictures too.

Crohn'sPhase 2 planned
Possible arrival: after 2030

Two treatments in one

Two different brakes on inflammation are combined to go further than one alone.

ABBV-466

AbbVie · Injection

Pathway: IL-23 + α4β7

Skyrizi + an anti-α4β7 (Entyvio’s family), given together. Gut lining healed at 6 months: 40% versus 22% with Skyrizi alone (trial with no placebo).

Crohn'sPhase 2; other AbbVie combinations being tested
Possible arrival: after 2030

SPY001, SPY002, SPY003

Spyre · Injection

Pathway: α4β7, TL1A, IL-23

Tested alone then together; the aim is one injection every 3 to 6 months.

UCPhase 2, combination results in 2027
Possible arrival: after 2030

MORF-057 + Omvoh

Lilly · Tablet + injection

Pathway: α4β7 + IL-23
UCPhase 2, results in 2027
Possible arrival: after 2030

More new tablets

New targets, still with no injection.

Emvistegrast

Gilead · Tablet

Pathway: α4β7

Like Entyvio, but as a tablet. At 12 weeks, 31% remission on the highest dose (59 patients) versus 8% on placebo (60 patients).

UCPhase 2 positive, Phase 3 planned for 2027
Possible arrival: around 2030

MORF-057

Lilly · Tablet

Pathway: α4β7

Another “Entyvio in a tablet”.

UCPhase 2b completed, results awaited
Crohn'sPhase 2
Possible arrival: after 2030

OD-001

Odyssey · Tablet

Pathway: RIPK2 (NOD2)

Blocks RIPK2, the relay just after NOD2, the best-known Crohn's gene.

UCPhase 2a with no placebo: 27% remission at 12 weeks, in 41 patients
Possible arrival: after 2030

ABBV-668

AbbVie · Tablet

Pathway: RIPK1

Blocks RIPK1, a switch for inflammation.

UCPhase 2
Crohn'sPhase 2
Possible arrival: after 2030

Zasocitinib

Takeda · Tablet

Pathway: TYK2

Blocks TYK2, a relay for inflammation.

UCPhase 2 completed, results by March 2027
Crohn'sPhase 2
Possible arrival: after 2030

Garutadustat

Insilico · Tablet

Pathway: HIF

Designed with the help of artificial intelligence. Helps the gut wall repair itself.

UCPhase 2a, results in 2027
Possible arrival: after 2030

Tamuzimod

Lilly (formerly Ventyx) · Tablet

Pathway: S1P

Same family as Velsipity.

UCPhase 2 met its endpoints, future uncertain
Possible arrival: uncertain

More new antibodies

Injections aimed at targets never used before in IBD.

ALTB-268

AltruBio · Injection

Pathway: PSGL-1

Calms overactive white blood cells.

UCPhase 2a with no placebo, Phase 2b in preparation
Possible arrival: after 2030

AZD7798

AstraZeneca · Injection

Pathway: CCR9

Removes the white blood cells “programmed” to go to the gut.

Crohn'sPhase 2a completed, results awaited
Possible arrival: after 2030

Lutikizumab

AbbVie · Injection

Pathway: IL-1

On its own, not effective enough in UC; now being tested with Skyrizi.

Crohn'sPhase 2 in combination
Possible arrival: after 2030

Eltrekibart

Lilly · Injection

Pathway: neutrophils (CXC)

Slows the arrival of the “firefighter” white blood cells.

UCPhase 2 completed, results awaited
Possible arrival: after 2030

BI 3032950

Boehringer Ingelheim

Pathway: TREM-1

Blocks an amplifier of inflammation.

UCPhase 2
Possible arrival: after 2030

Drugs from other diseases

Treatments already known in other conditions, such as diabetes and excess weight, are being tested in IBD.

Tirzepatide + Omvoh

Lilly · Injection

Pathway: GLP-1 / GIP + IL-23

For people who are overweight: aiming for remission and weight loss at the same time.

Crohn'sPhase 3b under way, including in France
UCPhase 3b under way
Possible arrival: results in 2028

GLP-1 drugs on their own

Ozempic, Mounjaro and others · Injection

Pathway: GLP-1

Large 2026 study: no fewer relapses, but no danger either. Not a treatment for IBD to date.

Crohn'sObservational studies
UCObservational studies
Possible arrival: not planned

Tackling a possible cause

MAP is a bacterium suspected of playing a role in some people with Crohn's. This is not proven yet.

Anti-MAP vaccine

University of Oxford and King's College · Injection

Pathway: MAP bacterium
Crohn'sPhase 2 against placebo, not yet open to recruitment (United Kingdom)
Possible arrival: after 2030

RHB-204

RedHill · Tablet

Pathway: MAP bacterium

3 antibiotics. Trial restricted to patients who carry MAP.

Crohn'sPhase 2 planned (funding being sought)
Possible arrival: after 2030
Recently stopped (so as not to raise false hopes)Etrasimod and ozanimod in Crohn's (not effective enough), rosnilimab in UC (failed in 2025), the anti-TNF tablet balinatunfib (stopped in 2026), Alofisel for fistulas (withdrawn in Europe at the end of 2024).

And further still

In research, a blood test picks up signs of Crohn's several years before diagnosis (about 4 years in a 2026 study). Trials are now trying to stop the disease from starting.

Antibodies that block IL-23 and TL1A at the same time are starting their first trials. And reprogramming the body’s defence cells (CAR-T), spectacular in lupus, could one day follow.